FDA Approves Edwards' PASCAL System for Tricuspid Valve Repair
EW sits 17% above its 52-week low of $74.66 on light trading volume (0.1× avg).
Summary
The FDA approved Edwards' PASCAL Precision System for transcatheter edge-to-edge repair in severe tricuspid regurgitation, opening a new US market for the company's structural heart franchise. A second approval covers PASCAL Ace with Capture Clarity for degenerative mitral TEER. Edwards says it is now the only US company offering both repair and replacement transcatheter therapies across the mitral and tricuspid valves. The win lands a week after the FDA escalated its warning on the Commander M delivery systems to a high-risk recall, giving the stock a counterweight to that negative regulatory headline. One-year results from the pivotal CLASP IITR tricuspid trial are due at the upcoming TCT scientific meeting, which will shape how quickly physicians adopt the new indication.
At the time of this announcement, EW was trading at $87.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $50.2B. The 52-week trading range was $74.66 to $96.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.